ArticleLaryngoscope investigative otolaryngology2026
Implementing a Rapid Response Pathway for Anaplastic Thyroid Cancer in a Universal Healthcare System.
Article in Laryngoscope investigative otolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Implementing a Rapid Response Pathway for Anaplastic Thyroid Cancer in a Universal Healthcare System.Laryngoscope investigative otolaryngology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To implement a multidisciplinary anaplastic thyroid cancer rapid response team (ARRT) pathway in a universal healthcare system and evaluate its impact on diagnostic and treatment timelines for patients with anaplastic thyroid cancer (ATC). Methods: This quasi-experimental study was conducted at a tertiary care cancer center in Canada. We compared 26 consecutive adult patients with confirmed ATC: 11 patients in the pre-pathway period (January 2015-June 2020) and 15 in the post-pathway period (July 2020-July 2023). The ARRT pathway incorporated early identification of suspected cases, image-guided biopsies with rapid on-site cytology evaluation, expedited staging and molecular analysis, coordinated same-day multidisciplinary consultations, and early palliative care involvement. Outcomes included time from initial clinical suspicion to staging completion, multidisciplinary assessment, and treatment initiation. Results: The ARRT pathway significantly reduced median time from initial suspicion to staging completion from 21 days (IQR: 12-45) to 6 days (IQR: 2-9) ( Conclusion: The ARRT pathway reduced diagnostic and treatment delays for ATC patients within a universal healthcare system. This rapid response model demonstrates feasibility and effectiveness in improving care coordination for rare aggressive malignancies. The approach provides a replicable four-phase implementation framework for similar healthcare systems globally. Level of Evidence: 3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.